Table 3 Efficacy parameters at Week 52 and Week 104 in the mITT analysis set [21, 22]
|  |  | CANA 100 mg (N = 483) | CANA 300 mg (N = 485) | GLIM (N = 482) |
|---|---|---|---|---|
LS mean change (SE) | LS mean change (SE) | LS mean change (SE) | ||
A1C, % | 52 weeks | −0.82 (0.04) | −0.93 (0.04) | −0.81 (0.04) |
|  | 104 weeks | −0.65 (0.04) | −0.74 (0.04) | −0.55 (0.04) |
SBP, mm Hg | 52 weeks | −3.3 (0.6) | −4.6 (0.6) | 0.2 (0.6) |
|  | 104 weeks | −2.0 (0.6) | −3.1 (0.6) | 1.7 (0.6) |
DBP, mm Hg | 52 weeks | −1.8 (0.4) | −2.5 (0.4) | −0.1 (0.4) |
|  | 104 weeks | −1.3 (0.4) | −2.2 (0.4) | −0.0 (0.4) |
BW, kg | 52 weeks | −3.7 (0.2) | −4.0 (0.2) | 0.7 (0.2) |
|  | 104 weeks | −3.6 (0.2) | −3.6 (0.2) | 0.8 (0.2) |